MedTrace Logo

Invasives Aspergillosis in Acute Myeloid Leukemia

NCT02900430 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 246

Last updated 2016-09-14

No results posted yet for this study

Summary

Patients with acute myeloid leukemia (AML) are at risk to develop severe infections whose invasive aspergillosis (IA). These infections are leading to an important morbidity and mortality. Antifungal prophylaxis is recommended by posaconazole for AML patients during neutropenia induced by induction chemotherapy. Their application is not uniform.

Conditions

Interventions

OTHER

Patients without antifungal prophylaxis

Epidemiology data: clinical and biological informations collecting

DRUG

Patients with antifungal prophylaxis

Hospitalized patients between 2012 and 2015 received Posaconazole prophylaxis during neutropenia period induced by induction or salvage chemotherapy.

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Principal Investigators

  • Gaelle Guillerm, MD · Department of Hematology, Brest Teaching Hospital

  • Lenaig Le Clech, MD · Department of Hematology, Brest Teaching Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02900430 on ClinicalTrials.gov